Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
Meiji Holdings said on June 30 that subsidiary Meiji Seika Pharma filed an application in Japan seeking an additional indication for ARCT-154, a self-amplifying mRNA vaccine against COVID-19, for booster use in adults. The vaccine was submitted for primary inoculations…
To read the full story
Related Article
- Meiji’s mRNA Vaccine, Daiichi’s XBB.1.5 Jab Up for Nov. 27 PAFSC Session
November 17, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
May 1, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
November 2, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…